Susan Molineaux, Calithera CEO (via Lightstone Ventures)
Still reeling from PhII failure, Calithera beefs up its oncology portfolio with a little help from Takeda
Calithera started the year by axing a third of its staff after a monumental Phase II flop in renal cell carcinoma. And while CEO …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
